A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

NCT07383506 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA Mutations
Advanced Solid Tumors, Adult
Endometrial Cancer
HR Positive/HER-2 Negative Breast Cancer
HER2-low Breast Cancer

Interventions

DRUG: CGT6297

Sponsor

Cogent Biosciences, Inc.